# SSGJ-612

Source: https://onco.cc/drugs/ssgj-612/  
OnCo record `ssgj-612` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SSGJ-612 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at HER2.

## Summary

SSGJ-612 is a monoclonal antibody developed by Shenyang Sunshine Pharmaceutical. Its target is HER2. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07646626, plans to enrol 150 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: Monoclonal antibody directed at HER2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of SSGJ-612: https://clinicaltrials.gov/search?intr=SSGJ-612

## Connected records

- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [3SBio](https://onco.cc/companies/3sbio/)
- trials: [SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors](https://onco.cc/trials/nct07646626/)

---
JSON: https://onco.cc/api/v1/entities/ssgj-612.json